Cargando…

Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials

BACKGROUND: Dapagliflozin, a novel inhibitor of sodium-glucose cotransporter-2 (SGLT-2), lowers blood glucose level by specifically inhibiting the activity of SGLT-2. Previous studies showed efficacy and safety of dapagliflozin combined with other antihyperglycemic agents in type 2 diabetes (T2DM),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Miao, Lv, Haihong, Xu, Xia, Wang, Jue, Lyu, Wenyi, Fu, Songbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709066/ https://www.ncbi.nlm.nih.gov/pubmed/31348290 http://dx.doi.org/10.1097/MD.0000000000016575

Ejemplares similares

Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2020)

Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India
por: Varshney, Amit, et al.
Publicado: (2023)

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
por: Saleem, Fatima
Publicado: (2017)

Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome
por: Cheng, Lan, et al.
Publicado: (2021)

The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy
por: Huang, Ying, et al.
Publicado: (2022)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta-analysis of randomized controlled trials
por: Huang, Yuxin, et al.
Publicado: (2021)

The efficacy of dapagliflozin for type 1 diabetes: a meta-analysis of randomized controlled studies
por: Ma, Jian, et al.
Publicado: (2021)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Effıcacy and safety of dapagliflozin on diabetic patients receiving high-doses of insulin
por: Sertbas, Meltem, et al.
Publicado: (2019)

Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials
por: Zhu, Hongmei, et al.
Publicado: (2013)

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China
por: Gu, Shuyan, et al.
Publicado: (2016)

Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial
por: Han, Kyung Ah, et al.
Publicado: (2023)

The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials
por: Sun, Yu-nan, et al.
Publicado: (2014)

Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
por: Alam, Fahmida, et al.
Publicado: (2019)

Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience
por: Scorsone, Alessandro, et al.
Publicado: (2018)

Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study
por: Kaku, Kohei, et al.
Publicado: (2014)

Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post Authorization Safety Study
por: Alguwaihes, Abdullah M.
Publicado: (2021)

A Network Meta-Analysis of the Dose–Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes
por: Li, Yinhui, et al.
Publicado: (2022)

A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy
por: Orme, Michelle, et al.
Publicado: (2014)

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia
por: Ji, Linong, et al.
Publicado: (2019)

The Clinical Efficacy and Safety of Stem Cell Therapy for Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Zhang, Yazhen, et al.
Publicado: (2020)

Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial
por: Ferreira-Hermosillo, Aldo, et al.
Publicado: (2020)

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
por: Stenlöf, K, et al.
Publicado: (2013)

Toll like receptor 4 gene Asp299Gly polymorphism increases the risk of diabetic microvascular complications: a meta analysis
por: Zhang, Yuqi, et al.
Publicado: (2022)

Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin
por: Yang, Ai-Yu, et al.
Publicado: (2020)

Association Between Coronary Artery Calcium Score and Bone Mineral Density in Type 2 Diabetes Mellitus with Different Visceral Fat Area
por: Yang, Ying, et al.
Publicado: (2022)

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study
por: Scott, Russell, et al.
Publicado: (2018)

Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials
por: Zhang, Yun-Jing, et al.
Publicado: (2018)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
por: Frías, Juan P., et al.
Publicado: (2018)

Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV
por: Strojek, Krzysztof, et al.
Publicado: (2021)

The efficacy of dapagliflozin combined with hypoglycemic drugs in treating type 2 diabetes: protocol for meta-analysis of randomized controlled trials
por: Sun, Yu-nan, et al.
Publicado: (2013)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open‐label, multicenter study
por: Seino, Yutaka, et al.
Publicado: (2017)

Efficacy of Dapagliflozin in Patients with Diabetes Mellitus Complicated with Coronary Artery Disease and Its Impact on the Vascular Endothelial Function
por: Ma, Fei, et al.
Publicado: (2022)

Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China
por: Zhaohu, Hao, et al.
Publicado: (2022)

Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial
por: Chen, Yuhong, et al.
Publicado: (2015)

Efficacy and safety of dapagliflozin in the treatment of chronic heart failure: A protocol for systematic review and meta-analysis
por: Dong, Xueyan, et al.
Publicado: (2021)

Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions
por: Vart, Priya, et al.
Publicado: (2022)

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus
por: Tamez, Hector E., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bhlb1l2qm55heva0kbudqcgfrt